Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04111445 · ClinicalTrials.gov registry record · Phase 1
Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors
A Phase 1 study, sponsored by Adagene.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT04111445: Clinical Trial Phase 1 study, sponsored by Adagene.
NCT04111445 is a Phase 1 study that was terminated before completion, run by Adagene. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04111445, a Phase 1 study, was terminated before completion, sponsored by Adagene.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
This is a FIH, open-label, Phase I dose-escalation study of ADG116 in subjects with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. ADG 116 administered intravenously (IV) over a period of 60-90 minutes. The study planned to treated 42 patients.
Interventions
- DRUG ADG116
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2019-08-29 |
| Est. Completion | 2021-04-27 |
| Phase | Phase 1 |
Why NCT04111445 stopped before completion
NCT04111445 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which ADG116 is the first listed.
NCT04111445 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04111445 about?
NCT04111445 is a clinical study titled "Study of ADG116 in Patients With Advanced/Metastatic Solid Tumors". This is a FIH, open-label, Phase I dose-escalation study of ADG116 in subjects with advanced/metastatic solid tumors. Study drug, ADG116, is an anti -CTLA-4 fully human monoclonal antibody that specifically binds to human CTLA-4. ADG 116 administered intravenously (IV) over a period of 60-90 minutes...
What is the current status of trial NCT04111445?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2019-08-29. Estimated completion is 2021-04-27.
What interventions are being tested in trial NCT04111445?
The interventions under investigation include: ADG116 (DRUG).
Who is sponsoring clinical trial NCT04111445?
This trial is sponsored by Adagene, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04111445's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI